RecruitingNCT04550377
Cannabidiol versus placebo for PTSD with or without traumatic brain injury
About this title
Read the official source — NCT04550377Medication studyAges 18–70United States
Understand this study
Who could participate?
This study is for people with PTSD. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 26, 2021
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 120
- Sponsor
- NYU Langone Health
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT04550377
- Official title
Show the full official title
Cannabidiol for Treating PTSD Symptoms and Neurocognitive Impairment in PTSD and PTSD Comorbid With TBI: A Placebo-controlled RCT With Neural-circuit Centered Precision Medicine Prediction of Response.
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
New York
Questions about this study
Who is behind this study?
The study sponsor is NYU Langone Health.
Does this study involve medication?
Yes. The study involves medication, including Cannabidiol and Placebo.
Who can participate?
This study is for people with PTSD. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
